Targeted Therapeutic Strategies in the Battle Against Pathogenic Bacteria
Open Access
- 12 May 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
Abstract
The emergence and rapid spread of antibiotic resistance in pathogenic bacteria constitute a global threat for public health. Despite ongoing efforts to confront this crisis, the pace of finding new potent antimicrobials is far slower than the evolution of drug resistance. The abuse of broad-spectrum antibiotics not only accelerates the formation of resistance but also imposes a burden on the intestinal microbiota, which acts a critical role in human homeostasis. As such, innovative therapeutic strategies with precision are pressingly warranted and highly anticipated. Recently, target therapies have achieved some breakthroughs by the aid of modern technology. In this review, we provide an insightful illustration of current and future medical targeted strategies, including narrow-spectrum agents, engineered probiotics, nanotechnology, phage therapy, and CRISPR-Cas9 technology. We discuss the recent advances and potential hurdles of these strategies. Meanwhile, the possibilities to mitigate the spread of resistance in these approaches are also mentioned. Altogether, a better understanding of the advantages, disadvantages, and mechanisms of action of these targeted therapies will be conducive to broadening our horizons and optimizing the existing antibacterial approaches.Keywords
This publication has 135 references indexed in Scilit:
- X-ray crystal structure of the streptococcal specific phage lysin PlyCProceedings of the National Academy of Sciences of the United States of America, 2012
- Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence studyThe Lancet Infectious Diseases, 2011
- Engineering microbes to sense and eradicate Pseudomonas aeruginosa , a human pathogenMolecular Systems Biology, 2011
- Gut inflammation provides a respiratory electron acceptor for SalmonellaNature, 2010
- Engineered bacterial communication prevents Vibrio cholerae virulence in an infant mouse modelProceedings of the National Academy of Sciences of the United States of America, 2010
- Synergism between a Novel Chimeric Lysin and Oxacillin Protects against Infection by Methicillin-Resistant Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 2010
- Pharmacokinetics and Safety Profile of the Human Anti- Pseudomonas aeruginosa Serotype O11 Immunoglobulin M Monoclonal Antibody KBPA-101 in Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2009
- Bacteriophage lysins as effective antibacterialsCurrent Opinion in Microbiology, 2008
- Identification and Characterization of Lactococcal-Prophage-Carried Superinfection Exclusion GenesApplied and Environmental Microbiology, 2008
- Phase II, Randomized, Double-Blind, Multicenter Study Comparing the Safety and Pharmacokinetics of Tefibazumab to Placebo for Treatment of Staphylococcus aureus BacteremiaAntimicrobial Agents and Chemotherapy, 2006